You can buy Lenakast at the lowest price in the online pharmacy Nextgen.ooo . Lenalidomide is a thalidomide derivative used to treat multiple myeloma and anemia in myelodysplastic syndromes of low to intermediate risk.
 
Lenalidomide (formerly CC-5013) is an immunomodulatory drug with potent antitumor, antiangiogenic, and anti-inflammatory properties. It is a 4-aminoglutamyl analogue of thalidomide and, like thalidomide, lenalidomide exists as a racemic mixture of the active forms S (-) and R (+). However, lenalidomide is much safer and more effective than thalidomide, with fewer side effects and toxicity. Thalidomide and its analogues, including lenalidomide, belong to the immunomodulatory imide drugs (also known as cereblon modulators), which are a class of immunomodulatory drugs containing an imide group. Lenalidomide acts through multiple mechanisms of action that promote malignant cell death and enhance host immunity. Available as oral capsules, lenalidomide is FDA and EU approved for the treatment of multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma in selected patients.
 
In hematologic malignancies, the immune system is compromised by altered cytokine networks in the tumor microenvironment, dysregulated T cell regulation of host-tumor immune interactions, and decreased NK cell activity. Lenalidomide is an immunomodulatory agent with antitumor, antiangiogenic, and anti-inflammatory properties. Lenalidomide exhibits direct cytotoxicity by enhancing apoptosis and inhibiting proliferation of malignant hematopoietic cells. It delays tumor growth in preclinical in vivo models of hematopoietic tumors, including multiple myeloma. Lenalidomide also limits tumor cell invasion or metastasis and inhibits angiogenesis.
 
Lenalidomide also mediates indirect antitumor effects through its immunomodulatory action: it suppresses the production of proinflammatory cytokines that are involved in various hematological malignancies. Lenalidomide enhances host immunity by stimulating T-cell proliferation and increasing natural killer (NK) cell activity. Lenalidomide is approximately 100-1000 times more potent in stimulating T-cell proliferation than thalidomide. In vitro, it enhances antibody-dependent cell-mediated cytotoxicity (ADCC), which is further enhanced when used in combination with rituximab. Due to its anti-inflammatory properties, lenalidomide has been studied in the context of inflammatory and autoimmune diseases such as amyotrophic lateral sclerosis.
 
Lenalidomide is a drug with multiple mechanisms of action. Lenalidomide exerts its immunomodulatory effects by altering cytokine production, regulating T-cell costimulation, and enhancing NK cell-mediated cytotoxicity. Lenalidomide directly inhibits the cullin ring E3 ubiquitin ligase complex: upon binding to cerblon, a substrate adaptor of the complex, lenalidomide modulates the substrate specificity of the complex by recruiting ligase substrate proteins including Ikaros (IKZF1), Aiolos (IKZF3), and CK1α. These substrates are then marked for ubiquitination and subsequent proteasomal degradation. IKZF1 and IKZF3 are B-cell transcription factors that are required for B-cell differentiation and malignant cell survival. IKZF3 also regulates the expression of interferon regulatory factor 4 (IRF4), which is a transcription factor that regulates a gene specific for aberrant myeloma. The immunomodulatory effect of lenalidomide can be partly explained by the degradation of IKZF3, since it is a repressor of the interleukin 2 (IL2) gene: as lenalidomide reduces IKZF3 levels, IL-2 production increases, thereby increasing the proliferation of natural killer (NK), NKT cells, and CD4+ T cells. Lenalidomide suppresses the production of proinflammatory cytokines TNF-α, IL-1, IL-6, and IL-12, while increasing the production of the anti-inflammatory cytokine IL-10. 3. Lenalidomide acts as a T cell costimulator that promotes the proliferation of CD3 T cells and increases IL-2 and IFN-γ production in T lymphocytes, which enhances NK cell cytotoxicity and ADCC. It suppresses the expression and function of T-regulatory cells, which are often abundant in some hematological malignancies.